SI3417875T1 - Formulacija imunoglobulina in metode za njegovo pripravo - Google Patents

Formulacija imunoglobulina in metode za njegovo pripravo

Info

Publication number
SI3417875T1
SI3417875T1 SI200432502T SI200432502T SI3417875T1 SI 3417875 T1 SI3417875 T1 SI 3417875T1 SI 200432502 T SI200432502 T SI 200432502T SI 200432502 T SI200432502 T SI 200432502T SI 3417875 T1 SI3417875 T1 SI 3417875T1
Authority
SI
Slovenia
Prior art keywords
preparation
immunoglobulin formulation
immunoglobulin
formulation
Prior art date
Application number
SI200432502T
Other languages
English (en)
Slovenian (sl)
Inventor
David J. Burke
Shaun E. Buckley
Sherwood Russ Lehrman
Barbara Horsey O'connor
James Callaway
Christopher Phillips
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32869424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3417875(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of SI3417875T1 publication Critical patent/SI3417875T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200432502T 2003-02-10 2004-02-09 Formulacija imunoglobulina in metode za njegovo pripravo SI3417875T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44581803P 2003-02-10 2003-02-10
EP18174115.8A EP3417875B1 (en) 2003-02-10 2004-02-09 Immunoglobulin formulation and method of preparation thereof

Publications (1)

Publication Number Publication Date
SI3417875T1 true SI3417875T1 (sl) 2021-01-29

Family

ID=32869424

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432502T SI3417875T1 (sl) 2003-02-10 2004-02-09 Formulacija imunoglobulina in metode za njegovo pripravo
SI200432441T SI2236154T1 (en) 2003-02-10 2004-02-09 THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200432441T SI2236154T1 (en) 2003-02-10 2004-02-09 THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION

Country Status (28)

Country Link
US (7) US20050053598A1 (enExample)
EP (4) EP3777880A1 (enExample)
JP (3) JP4728948B2 (enExample)
KR (1) KR20050110628A (enExample)
CN (2) CN1771053B (enExample)
AR (1) AR043144A1 (enExample)
AU (2) AU2004210679A1 (enExample)
CA (1) CA2515444C (enExample)
CL (1) CL2004000224A1 (enExample)
CY (2) CY1120574T1 (enExample)
DK (2) DK3417875T3 (enExample)
ES (1) ES2819011T3 (enExample)
HU (1) HUE051878T2 (enExample)
IL (1) IL170008A (enExample)
MX (1) MXPA05008409A (enExample)
MY (1) MY162623A (enExample)
NO (1) NO346070B1 (enExample)
PE (1) PE20050190A1 (enExample)
PT (2) PT2236154T (enExample)
RU (1) RU2358763C2 (enExample)
SI (2) SI3417875T1 (enExample)
SK (1) SK50672005A3 (enExample)
TR (1) TR201808801T4 (enExample)
TW (1) TWI367766B (enExample)
UA (1) UA82685C2 (enExample)
UY (1) UY28184A1 (enExample)
WO (1) WO2004071439A2 (enExample)
ZA (1) ZA200506159B (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3674322A1 (en) * 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
AU2003270330B2 (en) * 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
LT1729810T (lt) * 2004-04-02 2018-11-26 Swedish Orphan Biovitrum Ab (Publ) Il-1ra agregacijos sumažinimo būdas
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
NZ560844A (en) * 2005-03-08 2008-08-29 Pharmacia & Upjohn Co Llc Anti-MAdCAM antibody compositions
CA2607663C (en) 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0615745A2 (pt) * 2005-09-12 2011-05-24 Novimmune Sa formulação de anticorpo anti-cd3
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JP5193881B2 (ja) 2005-12-29 2013-05-08 セントカー・インコーポレーテツド ヒト抗ｉｌ−２３抗体、組成物、方法および用途
CA3022097C (en) 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
ES2827180T3 (es) * 2006-10-06 2021-05-20 Amgen Inc Formulaciones de anticuerpos estables
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
CA2677831A1 (fr) * 2007-02-12 2008-08-21 Lassaad Boujbel Le sucralose solution sterile sans conservateurs
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
TR201820837T4 (tr) * 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumab antikor formülasyonları.
WO2009003010A2 (en) * 2007-06-25 2008-12-31 Becton, Dickinson And Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
EP2237038B1 (en) * 2007-10-22 2015-04-29 Becton Dickinson and Company Medical articles coated with organopolysiloxane containing a protein solution and non-ionic surfactant
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
ES2406029T3 (es) 2008-04-15 2013-06-05 Grifols Therapeutics Inc. Ultrafiltración/diafiltración en dos fases
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
AU2009334090B2 (en) * 2008-12-29 2012-08-30 Samyang Biopharmaceuticals Corporation Pharmaceutical composition of lyophilized formulation and preparation method of the same
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
EP2419137A4 (en) * 2009-04-17 2013-01-09 Biogen Idec Inc COMPOSITIONS AND METHOD FOR TREATING ACUTE MYELOGENIC LEUKEMIA
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CN102655853B (zh) * 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
HRP20190690T1 (hr) * 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP3216462A3 (en) * 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
KR20130086144A (ko) 2010-05-28 2013-07-31 노보 노르디스크 에이/에스 항체 및 보존제를 포함하는 안정한 다중-투여 조성물
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
ES2654820T3 (es) 2010-10-25 2018-02-15 Biogen Ma Inc. Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM
HRP20161753T1 (hr) 2010-11-11 2017-02-10 Abbvie Biotechnology Ltd Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
RU2563346C2 (ru) 2011-03-31 2015-09-20 Мерк Шарп И Доум Корп. Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
BR112013030236A2 (pt) * 2011-05-26 2016-12-06 Glaxosmithkline Biolog Sa preparação em massa de vírus da dengue inativado ou uma composição imunogênica, e, preparação liofilizada de vírus da dengue inativado
US10995130B2 (en) * 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
ES2983564T3 (es) 2013-11-21 2024-10-23 Genmab As Formulación liofilizada de conjugado de anticuerpos y fármaco
US9932591B2 (en) 2013-12-18 2018-04-03 University Of Delaware Reduction of lipase activity in product formulations
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102210104B1 (ko) 2014-10-17 2021-02-01 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017015198A1 (en) * 2015-07-17 2017-01-26 Coherus Biosciences, Inc. Stable aqeous formulations of natalizumab
US10484453B2 (en) * 2015-07-29 2019-11-19 Xerox Corporation System and method for printing documents using print hardware and automatic context inference
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017121867A1 (en) 2016-01-13 2017-07-20 Genmab A/S Formulation for antibody and drug conjugate thereof
US10914720B2 (en) 2016-02-10 2021-02-09 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
KR102686858B1 (ko) 2017-12-06 2024-07-19 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11667702B2 (en) 2018-03-08 2023-06-06 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019251453A1 (en) 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
JP2021521168A (ja) * 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 安定な抗体製剤
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
BR112021008873A8 (pt) 2018-11-07 2023-04-11 Merck Sharp & Dohme Formulação
BR112021009287A2 (pt) 2018-11-20 2021-10-26 Janssen Biotech, Inc. Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
WO2020131763A2 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
TWI827732B (zh) * 2018-12-24 2024-01-01 大陸商遠大賽威信生命科學（南京）有限公司 用於治療b型肝炎的藥物製劑及其製備方法和用途
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
MX2021014756A (es) * 2019-06-07 2022-01-18 Argenx Bvba Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
EP3983079A1 (en) * 2019-06-11 2022-04-20 MacroGenics, Inc. Pharmaceutical formulations of bi-specific diabodies and use of the same
AU2020319897A1 (en) * 2019-08-01 2022-02-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US20230041642A1 (en) * 2019-12-16 2023-02-09 Nipro Corporation Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
TW202140552A (zh) 2020-01-08 2021-11-01 比利時商阿根思公司 用於治療天皰瘡病症的方法
EP4090368A1 (en) * 2020-01-13 2022-11-23 Aptevo Research and Development LLC Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
EP4096802A4 (en) * 2020-01-29 2024-07-03 Merck Sharp & Dohme LLC METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
US20230340131A1 (en) * 2020-11-12 2023-10-26 Dr. Reddy’S Laboratories Limited Stable aqueous high concentration formulation of integrin antibody
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
CA3258002A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN BINDING MOLECULES AND METHODS OF USE
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2560155C2 (de) * 1974-03-08 1984-04-26 Teijin Ltd., Osaka Humanimmunglobulin-Derivat
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0417191B1 (en) * 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
DE19912637A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN101333256A (zh) 1999-03-25 2008-12-31 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
ES2298236T3 (es) * 2001-01-31 2008-05-16 Evonik Rohm Gmbh Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
EP3674322A1 (en) 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
WO2004100984A1 (en) 2003-05-13 2004-11-25 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
TR201820837T4 (tr) 2007-06-14 2019-01-21 Biogen Ma Inc Natalizumab antikor formülasyonları.

Also Published As

Publication number Publication date
US20120328614A1 (en) 2012-12-27
CY1120574T1 (el) 2019-07-10
MXPA05008409A (es) 2005-10-05
EP3777880A1 (en) 2021-02-17
TWI367766B (en) 2012-07-11
EP1592440A4 (en) 2007-07-11
CN103040732B (zh) 2015-04-01
NO20054164L (no) 2005-09-07
US8349321B2 (en) 2013-01-08
CN1771053A (zh) 2006-05-10
NO346070B1 (no) 2022-01-31
PT2236154T (pt) 2018-06-26
US20210292419A1 (en) 2021-09-23
HUE051878T2 (hu) 2021-03-29
DK2236154T3 (en) 2018-06-25
JP2011088913A (ja) 2011-05-06
CA2515444A1 (en) 2004-08-26
UY28184A1 (es) 2004-09-30
US20050053598A1 (en) 2005-03-10
US8815236B2 (en) 2014-08-26
ZA200506159B (en) 2006-10-25
AU2010202254A1 (en) 2010-06-24
CN103040732A (zh) 2013-04-17
AU2010202254B2 (en) 2012-02-23
US10954303B2 (en) 2021-03-23
HK1182021A1 (en) 2013-11-22
US20100021461A1 (en) 2010-01-28
CN1771053B (zh) 2012-10-03
EP1592440A2 (en) 2005-11-09
EP3417875B1 (en) 2020-06-17
PE20050190A1 (es) 2005-03-21
SI2236154T1 (en) 2018-08-31
JP4728948B2 (ja) 2011-07-20
US8900577B2 (en) 2014-12-02
JP2006517233A (ja) 2006-07-20
UA82685C2 (uk) 2008-05-12
KR20050110628A (ko) 2005-11-23
US20130071386A1 (en) 2013-03-21
AR043144A1 (es) 2005-07-20
CL2004000224A1 (es) 2005-01-21
ES2819011T3 (es) 2021-04-14
AU2004210679A1 (en) 2004-08-26
CA2515444C (en) 2014-04-01
WO2004071439A3 (en) 2005-07-07
EP2236154A1 (en) 2010-10-06
MY162623A (en) 2017-06-30
TR201808801T4 (tr) 2018-07-23
RU2358763C2 (ru) 2009-06-20
JP2014028831A (ja) 2014-02-13
IL170008A (en) 2015-05-31
SK50672005A3 (sk) 2006-03-02
EP2236154B1 (en) 2018-05-30
TW200505478A (en) 2005-02-16
CY1123667T1 (el) 2022-03-24
US20180194843A1 (en) 2018-07-12
PT3417875T (pt) 2020-08-24
RU2005128280A (ru) 2006-06-10
EP3417875A1 (en) 2018-12-26
DK3417875T3 (da) 2020-08-31
WO2004071439A2 (en) 2004-08-26
US20150044206A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
TWI367766B (en) Immunoglobulin formulation and method of preparation thereof
HUE038498T2 (hu) Immunglobulin készítmény és elõállítási módszere
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
PL1698640T5 (pl) Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
EP1648316A4 (en) VERTEBRAL RETENTION AND CLEARANCE DEVICE AND METHOD OF USE
IL201409A0 (en) Cd40 antibody formulation and methods
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL169648A0 (en) Novel structures and method of preparation
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
SG115668A1 (en) Projection system and method of use thereof
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
AU2002246950A1 (en) Hydrocapsules and method of preparation
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
AU2003282593A8 (en) Polyphenolamine composition and method of use
EP1710584A4 (en) METHOD OF MEASURING LIPOARABINOMANANE AND ITS USE
GB0217372D0 (en) Psoriasis formulation and method of preparation
GB0223719D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
EP1616020A4 (en) ANTI-CR1 ANTIBODIES WITH REDUCED IMMUNOGENICITY AND COMPOSITIONS AND TREATMENT METHODS BASED ON THEM
GB0217269D0 (en) Psoriasis formulation and method of preparation
GB2408013B (en) Building components and method of manufacture
PL356684A1 (en) Method of receiving dietetic-therapeutic preparations and their application
AU2003906485A0 (en) Method and device for preparation of interconnecting material
IL155942A0 (en) Simple attachment bio-electrode and method of manufacture